IDEAYA BIOSCIENCES INC

IDEAYA insider Ruiz Briseno’s July 7, 2026 buy‑sell‑exercise move shows deep confidence in the company’s oncology pipeline and hints at future upside for shareholders.

Insider buying shows Ideaya’s leaders stay bullish on oncology trials—high‑risk, high‑reward, but a potentially attractive entry point for growth‑focused investors.